Medication safety

Important safety information for compounded semaglutide and compounded tirzepatide.

Name: Fifty 410
Address: US
Price range: $$

Fifty 410 offers compounded medications only. They are not FDA-approved, and FDA has not reviewed them for safety, effectiveness, or quality. Read this page before you start and keep it for reference: it summarises the known risks of semaglutide and tirzepatide, drawn from published prescribing information and FDA safety communications. Your prescription label and your provider’s directions always take precedence.

Compounded semaglutide Compounded tirzepatide

Compounded medications onlyNot FDA-approved or reviewedLast updated 2 September 2026

Before you start

Read this page and the information sheet that comes with your prescription, and keep both for reference.
Your prescription label and your provider’s written directions take precedence over anything on this website.
Tell your provider about everything you take (prescription medicines, over-the-counter medicines, vitamins, and herbal supplements) and about every health condition, including ones you think are unrelated.
Tell every healthcare professional who treats you, including dentists and surgical teams, that you use a GLP-1 medication.
Website support staff cannot give medical advice. Medical questions go to your provider through the patient portal; questions about how a preparation was made go to the dispensing pharmacy.

About compounded medications

Fifty 410 offers compounded medications only. Compounded semaglutide and compounded tirzepatide are not FDA-approved products. What that means in practice:

FDA does not review compounded drugs for safety, effectiveness, or quality before they are dispensed. Compounded drugs are not FDA-approved, and they are not generic versions of any FDA-approved product.
The concentration, form (usually a vial and syringe), inactive ingredients, and storage requirements of a compounded preparation are specific to the pharmacy that prepares it. The pharmacy label and package insert describe the specific preparation you receive.
Some compounded preparations include additional ingredients. Ask the pharmacy for the full ingredient list if you have allergies or sensitivities.
The pharmacy that prepares your medication is independent of Fifty 410 and is licensed in the state where it operates. Fifty 410 does not compound, manufacture, or dispense medication.
FDA has received reports of adverse events and dosing errors involving compounded semaglutide and tirzepatide. Most dosing errors involved patients drawing up the wrong amount from a vial. The measuring guidance on this page is intended to reduce that risk.

Important safety information

Compounded semaglutide

GLP-1 receptor agonist. Compounded; not FDA-approved.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist administered by injection under the skin when prescribed.

Compounded semaglutide is prepared by a licensed compounding pharmacy for an individual patient under a prescription. It is not an FDA-approved product: FDA has not reviewed it for safety, effectiveness, or quality. It is usually supplied as a multi-dose vial with syringes. The safety information below summarises the known risks of semaglutide, drawn from published prescribing information and FDA safety communications.

Boxed warning: risk of thyroid C-cell tumors

In studies with rodents, semaglutide caused thyroid C-cell tumors. It is not known whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in people.

Do not use semaglutide if you or any of your family have ever had MTC, or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Symptoms to report: Tell your provider right away if you get a lump or swelling in your neck, hoarseness that does not go away, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.

Do not use semaglutide if

You or a member of your family has ever had medullary thyroid carcinoma (MTC).
You have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
You have had a serious allergic reaction to semaglutide or to any ingredient in the compounded preparation. Ask the pharmacy for the full ingredient list.
You are under 18. Fifty 410 serves adults only.

Before you start, tell your provider if you have or have had

Pancreas problems, including a history of pancreatitis.
Kidney problems or a history of kidney disease.
Gallbladder problems, including gallstones.
Type 1 or type 2 diabetes, especially if you take insulin or a sulfonylurea, and any history of diabetic retinopathy (diabetes-related eye disease).
Severe stomach or intestinal problems, such as gastroparesis (slow stomach emptying), severe reflux, or a history of bowel obstruction.
Depression, suicidal thoughts, or any other mental health condition, now or in the past.
Thyroid problems, including any personal or family history of thyroid cancer.
Heart problems, including a history of a fast or irregular heartbeat.
A planned surgery or procedure that uses anesthesia or deep sedation.
A history of an eating disorder.
Heavy alcohol use, or use of any other medicine, supplement, or product intended for weight loss.
Pregnancy, plans to become pregnant, or breastfeeding.
Any allergy to a medicine, food, or preservative.

Medicines to watch

Tell your provider about every medicine, vitamin, and supplement you take. These groups need particular attention with semaglutide.

Insulin and sulfonylureas

Using semaglutide with insulin, or with a medicine that makes the pancreas release insulin (for example glipizide, glimepiride, or glyburide), raises the risk of low blood sugar. Your prescriber may need to adjust those medicines. Know the symptoms of hypoglycemia listed under serious side effects.

Medicines you take by mouth

Semaglutide slows stomach emptying, which can change how quickly oral medicines are absorbed. Tell your provider about every oral medicine, especially those that need steady blood levels or careful timing, such as warfarin, seizure medicines, thyroid medicine, and oral contraceptives.

Other GLP-1 medicines

Do not use semaglutide together with any other product that contains semaglutide, or with another GLP-1 receptor agonist such as tirzepatide, liraglutide, dulaglutide, or exenatide.

Weight-loss products and supplements

Tell your provider about any prescription, over-the-counter, or herbal product you take for weight, appetite, or energy, including stimulants.

Pregnancy and breastfeeding

Semaglutide may harm an unborn baby. Do not use it during pregnancy, and tell your provider right away if you become pregnant while using it.
Because semaglutide stays in the body for a long time, stop using it at least 2 months before a planned pregnancy.
Weight loss offers no benefit during pregnancy and may harm the baby.
It is not known whether semaglutide passes into breast milk. Talk to your provider before using it while breastfeeding.

Common side effects

The most common side effects reported with semaglutide are digestive. They are most frequent when starting and after a dose change, and many people find they ease over time.

Nausea
Diarrhea
Vomiting
Constipation
Stomach (abdominal) pain
Headache
Tiredness (fatigue)
Indigestion or heartburn
Dizziness
Bloating, belching, or gas
Stomach flu (gastroenteritis)
Low blood sugar in people with type 2 diabetes
Injection-site reactions
Hair loss
Changes in the way things taste

These are not all the possible side effects. Tell your provider about any side effect that bothers you or does not go away. General guidance on managing nausea, constipation, diarrhea, fatigue, reflux, and sulfur burps is in patient education.

Serious side effects

Semaglutide may cause serious side effects, including the following. The list is not complete.

Inflammation of the pancreas (pancreatitis)
Severe pain in the stomach area that does not go away, with or without vomiting. The pain may spread to your back.
What to do: Stop using semaglutide and get medical help right away.
Gallbladder problems
Pain in the upper stomach, fever, yellowing of the skin or the whites of the eyes (jaundice), or clay-colored stools.
What to do: Contact your provider right away.
Low blood sugar (hypoglycemia)
Dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery. The risk is higher if you also use insulin or a sulfonylurea.
What to do: Treat low blood sugar the way your provider has shown you and contact them. Call 911 if someone is confused, cannot swallow safely, or passes out.
Kidney problems (kidney failure)
Nausea, vomiting, or diarrhea that lead to dehydration can cause kidney problems, or make existing kidney problems worse.
What to do: Drink fluids to lower the chance of dehydration. Contact your provider if you cannot keep fluids down or are passing very little urine.
Serious allergic reactions
Swelling of the face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; a very rapid heartbeat.
What to do: Stop using semaglutide and get medical help right away.
Changes in vision in people with type 2 diabetes
Any change in your vision during treatment.
What to do: Tell your provider.
Increased heart rate
Feeling your heart racing or pounding in your chest while at rest, lasting for several minutes.
What to do: Tell your provider.
Depression or thoughts of suicide
New or worsening depression, thoughts about harming yourself, or any unusual change in mood or behavior.
What to do: Pay attention to any change and contact your provider right away. In the US you can call or text 988 to reach the Suicide and Crisis Lifeline at any time.
Severe stomach problems
Stomach problems that are severe or will not go away. Semaglutide is not recommended for people with severe gastroparesis, and blockage of the intestine (ileus) has been reported after approval.
What to do: Contact your provider.
Food or liquid entering the lungs during a procedure (pulmonary aspiration)
Semaglutide can leave food in the stomach even after fasting, which matters if you receive general anesthesia or deep sedation.
What to do: Tell every healthcare professional treating you, including before any surgery, endoscopy, or dental procedure, that you use semaglutide. Your surgical or anesthesia team will tell you whether and when to pause it.

How it is taken

Semaglutide is administered by injection under the skin (subcutaneously) when prescribed. Follow the schedule on your prescription label; your provider sets the dose and any change to it.
Inject into the stomach area (at least 2 inches from the navel), the front of the thigh, or the back of the upper arm. Use a different spot each week, and avoid skin that is bruised, scarred, tender, or hard.
Do not inject into a muscle or a vein. If you also use insulin, never mix the two in one syringe; you may inject them in the same body area, but not right next to each other.
Never share your vial, syringes, or needles with anyone else, even if the needle has been changed. Sharing can pass on serious infections.
If you miss a dose, follow the pharmacy label or ask your provider or pharmacist what to do. Never take a double dose to make up for a missed one.
Do not stop, restart, or change how you use the medication on your own. Talk to your provider first.

The injection guide walks through handling a vial and syringe step by step.

Sources for this section

FDA-approved prescribing information and Medication Guides for semaglutide injection products, via DailyMed (U.S. National Library of Medicine). https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=semaglutide

Important safety information

Compounded tirzepatide

Dual GIP and GLP-1 receptor agonist. Compounded; not FDA-approved.

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist administered by injection under the skin when prescribed.

Compounded tirzepatide is prepared by a licensed compounding pharmacy for an individual patient under a prescription. It is not an FDA-approved product: FDA has not reviewed it for safety, effectiveness, or quality. It is usually supplied as a multi-dose vial with syringes. The safety information below summarises the known risks of tirzepatide, drawn from published prescribing information and FDA safety communications.

Boxed warning: risk of thyroid C-cell tumors

In studies with rats, tirzepatide caused thyroid C-cell tumors. It is not known whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in people.

Do not use tirzepatide if you or any of your family have ever had MTC, or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Do not use tirzepatide if

You or a member of your family has ever had medullary thyroid carcinoma (MTC).
You have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
You have had a serious allergic reaction to tirzepatide or to any ingredient in the compounded preparation. Ask the pharmacy for the full ingredient list.
You are under 18. Fifty 410 serves adults only.

Before you start, tell your provider if you have or have had

Pancreas problems, including a history of pancreatitis.
Kidney problems or a history of kidney disease.
Gallbladder problems, including gallstones.
Type 1 or type 2 diabetes, especially if you take insulin or a sulfonylurea, and any history of diabetic retinopathy (diabetes-related eye disease).
Severe stomach or intestinal problems, such as gastroparesis (slow stomach emptying), severe reflux, or a history of bowel obstruction.
Depression, suicidal thoughts, or any other mental health condition, now or in the past.
Thyroid problems, including any personal or family history of thyroid cancer.
Heart problems, including a history of a fast or irregular heartbeat.
A planned surgery or procedure that uses anesthesia or deep sedation.
A history of an eating disorder.
Heavy alcohol use, or use of any other medicine, supplement, or product intended for weight loss.
Use of birth control pills or any other oral hormonal contraceptive.
Pregnancy, plans to become pregnant, or breastfeeding.
Any allergy to a medicine, food, or preservative.

Medicines to watch

Tell your provider about every medicine, vitamin, and supplement you take. These groups need particular attention with tirzepatide.

Insulin and sulfonylureas

Using tirzepatide with insulin, or with a medicine that makes the pancreas release insulin (for example glipizide, glimepiride, or glyburide), raises the risk of low blood sugar. Your prescriber may need to adjust those medicines. Know the symptoms of hypoglycemia listed under serious side effects.

Birth control pills

Tirzepatide slows stomach emptying and may reduce how well oral hormonal contraceptives work. Published prescribing information for tirzepatide advises switching to a non-oral method, or adding a barrier method such as condoms, for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase. Discuss this with your provider before you start.

Medicines you take by mouth

Slower stomach emptying can change how quickly oral medicines are absorbed. Tell your provider about every oral medicine, especially those that need steady blood levels or careful timing, such as warfarin, digoxin, seizure medicines, and thyroid medicine.

Other GLP-1 medicines

Do not use tirzepatide together with any other product that contains tirzepatide, or with a GLP-1 receptor agonist such as semaglutide, liraglutide, dulaglutide, or exenatide.

Weight-loss products and supplements

Tell your provider about any prescription, over-the-counter, or herbal product you take for weight, appetite, or energy, including stimulants.

Pregnancy and breastfeeding

Tirzepatide may harm an unborn baby. Do not use it during pregnancy, and tell your provider right away if you become pregnant while using it.
If you could become pregnant, talk to your provider about contraception before you start, keeping in mind the interaction with birth control pills described above.
Weight loss offers no benefit during pregnancy and may harm the baby.
It is not known whether tirzepatide passes into breast milk. Talk to your provider before using it while breastfeeding.

Common side effects

The most common side effects reported with tirzepatide are digestive. They are most frequent when starting and after a dose change, and many people find they ease over time.

Nausea
Diarrhea
Vomiting
Constipation
Stomach (abdominal) pain
Indigestion or heartburn
Decreased appetite
Injection-site reactions
Tiredness (fatigue)
Allergic-type reactions such as rash or itching
Belching
Hair loss

Serious side effects

Tirzepatide may cause serious side effects, including the following. The list is not complete.

Severe stomach problems
Stomach problems that are severe or will not go away. Tirzepatide is not recommended for people with severe gastroparesis, and blockage of the intestine (ileus) has been reported after approval.
What to do: Contact your provider.
Kidney problems (kidney failure)
Nausea, vomiting, or diarrhea that lead to dehydration can cause kidney problems, or make existing kidney problems worse.
What to do: Drink fluids to lower the chance of dehydration. Contact your provider if you cannot keep fluids down or are passing very little urine.
Gallbladder problems
Pain in the upper stomach, fever, yellowing of the skin or the whites of the eyes (jaundice), or clay-colored stools.
What to do: Contact your provider right away.
Inflammation of the pancreas (pancreatitis)
Severe pain in the stomach area that does not go away, with or without vomiting. The pain may spread to your back.
What to do: Stop using tirzepatide and get medical help right away.
Serious allergic reactions
Swelling of the face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; a very rapid heartbeat.
What to do: Stop using tirzepatide and get medical help right away.
Low blood sugar (hypoglycemia)
Dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery. The risk is higher if you also use insulin or a sulfonylurea.
What to do: Treat low blood sugar the way your provider has shown you and contact them. Call 911 if someone is confused, cannot swallow safely, or passes out.
Changes in vision in people with type 2 diabetes
Any change in your vision during treatment.
What to do: Tell your provider.
Increased heart rate
Feeling your heart racing or pounding in your chest while at rest, lasting for several minutes.
What to do: Tell your provider.
Depression or thoughts of suicide
New or worsening depression, thoughts about harming yourself, or any unusual change in mood or behavior.
What to do: Pay attention to any change and contact your provider right away. In the US you can call or text 988 to reach the Suicide and Crisis Lifeline at any time.
Food or liquid entering the lungs during a procedure (pulmonary aspiration)
Tirzepatide can leave food in the stomach even after fasting, which matters if you receive general anesthesia or deep sedation.
What to do: Tell every healthcare professional treating you, including before any surgery, endoscopy, or dental procedure, that you use tirzepatide. Your surgical or anesthesia team will tell you whether and when to pause it.

How it is taken

Tirzepatide is administered by injection under the skin (subcutaneously) when prescribed. Follow the schedule on your prescription label; your provider sets the dose and any change to it.
Inject into the stomach area (at least 2 inches from the navel), the front of the thigh, or the back of the upper arm. Use a different spot each week, and avoid skin that is bruised, scarred, tender, or hard.
Do not inject into a muscle or a vein. If you also use insulin, never mix the two in one syringe; you may inject them in the same body area, but not right next to each other.
Never share your vial, syringes, or needles with anyone else, even if the needle has been changed. Sharing can pass on serious infections.
If you miss a dose, follow the pharmacy label or ask your provider or pharmacist what to do. Never take a double dose to make up for a missed one.
Do not stop, restart, or change how you use the medication on your own. Talk to your provider first.

The injection guide walks through handling a vial and syringe step by step.

Sources for this section

FDA-approved prescribing information and Medication Guides for tirzepatide injection products, via DailyMed (U.S. National Library of Medicine). https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=tirzepatide

Measuring, handling, and storing a compounded dose

Compounded preparations usually come as a vial with separate syringes, so the dose is measured by you rather than set by a pen. Most reported errors with compounded GLP-1 medications come from measuring.

Measuring and handling

Use only the syringes supplied or specified by the pharmacy. Syringes are marked in units or in milliliters, and the label tells you which. Do not convert between milligrams, milliliters, and units yourself.
Before your first dose, confirm with the pharmacist or your provider exactly which mark on the syringe you should draw up to. If the number on the label and the number you were told do not match, do not inject; call the pharmacy.
Look at the solution before each dose. It should be clear and colorless. Do not use it if it is cloudy, discolored, or has particles in it.
Use a new sterile needle and syringe for every injection. Dispose of used sharps in an FDA-cleared sharps container or a heavy-duty plastic container with a tight lid, never in household trash or recycling.
Discard the vial after the beyond-use date on the pharmacy label, even if medication remains.

Storage

Store vials as the pharmacy label directs. Most compounded preparations are kept in the refrigerator, in the carton, away from light and heat.
Do not freeze, and do not use a vial that has been frozen.
Ask the pharmacy how long a vial may stay at room temperature, for example when travelling, and keep it cold with an insulated pack.
Keep all medication, syringes, and needles out of the reach of children and pets.

If you take too much

Taking more than prescribed can cause severe nausea, vomiting, and low blood sugar. If you think you have taken too much, call Poison Control at 1-800-222-1222 or get medical help right away, even if you feel well.
Because these medications stay in the body for about a week, the effects of an overdose can last for several days and may need medical observation.

Reporting side effects

Your provider

Report side effects to your provider through the patient portal. If a side effect is serious, seek care first and report afterwards.

FDA MedWatch

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit fda.gov/medwatch or call 1-800-FDA-1088 (1-800-332-1088).

The dispensing pharmacy

Report a problem with a preparation itself (appearance, packaging, labeling) directly to the pharmacy. Its contact details are on the label.

Open the patient portal Report to FDA MedWatch

Compounded only, and not affiliated with any manufacturer

Fifty 410 offers compounded medications only. Compounded semaglutide and compounded tirzepatide are not FDA-approved products, are not generic versions of any FDA-approved product, and have not been reviewed by FDA for safety, effectiveness, or quality. Fifty 410 does not claim that any compounded medication is the same as, equivalent to, or a substitute for any other product. Fifty 410 and the pharmacies it works with are not affiliated with, sponsored by, or endorsed by any pharmaceutical manufacturer.

General references

U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded-injectable-semaglutide-products
U.S. Food and Drug Administration. Human drug compounding. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
U.S. Food and Drug Administration. MedWatch: the FDA safety information and adverse event reporting program. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
Poison Help. America’s Poison Centers. https://www.poisonhelp.org

Patient educationManaging common side effects, and when to contact your provider.When to contact your providerGreen, yellow, and red zone symptoms.Injection guideStep-by-step handling of a vial and syringe.Weight management programHow provider review, pricing, and fulfillment work.

This page was last updated 2 September 2026. It is general information and does not replace the directions that come with your prescription.

Questions about your prescription?

Medical questions go to your provider through the patient portal. Questions about an order, billing, or the website go to the support team.

Open the patient portal Contact support